Floatz logo

Adebrelimab

Second-line Treatment

Sun Yat-sen UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Second-line Treatment cohort.

Asset / SponsorPhaseRating
Fruquintinib
Sun Yat-sen University
Phase 2CCC
Carboplatin
Second Affiliated Hospital of Zunyi Medical University
Phase 2CCC
Chir-258
Novartis Pharmaceuticals
Phase 2CCC
Toripalimab
Tianjin Medical University Cancer Institute and Hospital
Phase 1CC

Same molecule, other indications

Adebrelimab is also rated in:

Metastatic Colon CancerDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
67 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →